Quick Comparison

Azelaic AcidEGF (Epidermal Growth Factor)
Typical ConcentrationOTC: 10% (The Ordinary). Prescription: 15% gel (Finacea for rosacea), 20% cream (Azelex for acne). Apply twice daily. Well-tolerated but may sting/itch initially. Full effects at 8-12 weeks.Concentrations vary by product (typically measured in ppm or sh-oligopeptide-1 percentage). Applied once or twice daily. Best used after procedures or on aging skin. Apply before oils/occlusives. Store in refrigerator for stability.
ApplicationTopical (gel, cream, serum). Slightly gritty texture in some formulations. Apply to clean skin.Topical (serum, cream, ampoule). Apply to clean skin. Temperature-sensitive — some products require refrigeration.
Research Papers9 papers10 papers
Categories

Mechanism of Action

Azelaic Acid

Azelaic acid exhibits multi-modal activity: (1) Tyrosinase inhibition—competitively inhibits tyrosinase selectively in hyperactive melanocytes (melasma, PIH) while sparing normal ones; may involve mitochondrial enzyme interference in dysregulated melanocytes. (2) Antimicrobial—bacteriostatic against Cutibacterium acnes by inhibiting bacterial protein synthesis. (3) Comedolytic—normalizes follicular keratinization, reducing hyperkeratinization and corneocyte cohesion; may modulate keratinocyte differentiation. (4) Anti-inflammatory—scavenges ROS, inhibits neutrophil free radicals, reduces pro-inflammatory cytokines. Inhibits 5-alpha-reductase in sebocytes, potentially reducing sebum. Multi-pathway activity explains efficacy in acne, rosacea, and hyperpigmentation. Safe during pregnancy.

EGF (Epidermal Growth Factor)

EGF binds EGFR/ErbB1 on keratinocytes and fibroblasts, triggering dimerization and autophosphorylation. Activates MAPK/ERK (Ras-Raf-MEK-ERK) and PI3K/AKT pathways, promoting proliferation, migration (actin reorganization, focal adhesion turnover), and differentiation. Upregulates cyclin D1, inhibits p27. Stimulates fibroblast collagen types I/III and hyaluronic acid via HAS2. In wound healing, accelerates re-epithelialization via keratinocyte migration and reduces scarring via TGF-beta modulation. For anti-aging, promotes cellular renewal and extracellular matrix production. Theoretical cancer concern from EGFR's growth role — topical EGF has not been shown to penetrate to basal layer or systemic circulation significantly.

Risks & Safety

Azelaic Acid

Common

Stinging, burning, itching on initial application (usually subsides within 2 weeks). Mild dryness.

Serious

None. Safe during pregnancy and breastfeeding.

Rare

Allergic contact dermatitis, hypopigmentation (rare at cosmetic concentrations).

EGF (Epidermal Growth Factor)

Common

Very well-tolerated.

Serious

Theoretical concern about promoting growth of pre-existing skin cancers (unproven but debated).

Rare

Mild irritation.

Full Profiles